Global Anti Asthma Drugs Market Research Report – Forecast to 2022

Global Anti Asthma Drugs Market Research Report – Forecast to 2022

ID: MRFR/Pharma/1736-HCRR | August, 2018 | Region: Global | 85 pages | Half-Cooked Research Reports

Global anti-asthma drugs market Information, by     type of asthma (allergic (extrinsic) and non-allergic (intrinsic) asthma), by asthma trigger type (child-onset asthma, adult-onset asthma, exercise-induced asthma, cough-induced asthma, occupational asthma, nocturnal asthma, steroid-resistant asthma (severe asthma)), by drug class (bronchodilators (beta agonists, anti-cholinergics, xanthines), leukotriene antagonists, mast cell stabilizers,  corticosteroids, monoclonal antibody), by therapy (reliever treatment and maintenance treatment) and by route of administration (oral, inhaled, intravenous, subcutaneous)- Forecast to 2022

Market Synopsis of Global anti-asthma drugs market:


Market Scenario:


Asthma is a chronic lung disease characterized by hyper responsiveness of tracheobronchial smooth muscle to stimuli, resulting in narrowing and inflammation of air tubes, accompanied by increased secretion, swelling and build-up of tissue fluid. Symptoms include tight chest, wheezing, cough and may be limitation of activity due to difficulty in breathing.


Approximately, 300 million people suffer from asthma in 2015 and the figures are mounting which is blamed on increased pollution and unhealthy lifestyles. This has bloated the market to around USD 18.9 billion as of 2015 which is expected to reach USD 28.3 billion as of 2022, resulting in a CAGR of 5.94%. The factors favoring the growth of the market are growing awareness of the benefits of modern drug therapy, strong pipeline of anti-asthma drugs with some novel molecules, growth in patients due to increasing pollution and great potential of biologics which is anticipated to dominate the future market etc.


The constraining factors are loss of patents of leading brands, such as Advair and Symbicort, increasing fragmentation of markets and generic penetration. It is heartening to note that we anticipate that the growth factors will overwhelm the constraints and the market may take a strong growth due to commercialization of the biologics segment.


Study Objectives Global anti-asthma drugs market:



  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global anti-asthma drugs market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors - price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries - Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by type (allergic (extrinsic) and non-allergic (intrinsic)), by trigger type (child-onset, adult-onset, exercise-induced, cough-induced, occupational, nocturnal, steroid-resistant), by therapy (reliever treatment and maintenance treatment), by drug class (Bronchodilators (beta agonists, anti-cholinergics, xanthines), leukotriene antagonists, mast cell stabilizers, corticosteroids, monoclonal antibody) and by route of administration (oral, inhaled, intravenous, subcutaneous)

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.




 


Global anti-asthma drugs market, by Region 2015 & 2022 (USD million)Global Anti Asthma Drugs Market


 


Intended Audience:



  • Global anti-asthma drugs manufacturers

  • Global anti-asthma drugs suppliers

  • Research and development Laboratories

  • Market Research and Consulting Service Providers




Key Players for Global anti-asthma drugs market:


GlaxoSmithKline plc., Merck & Co., Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries, Novartis International AG, Boehringer Ingelheim, Sunovion Pharmaceuticals Inc.


Segments:


Global anti-asthma drugs market has been segmented on the basis of by type, trigger, therapy, drug class and by route of administration.


Regional Analysis of Global anti-asthma drugs market:


Globally North America is the largest market for anti-asthma drugs. Europe is the second-largest market for anti-asthma drugs. The developing region especially Asia Pacific is accounting for major newer cases due to greater screening and better health care facilities distribution. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future.


The report for Global Anti-Asthma Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Table of Contents

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s five forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global anti-asthma drugs market, by type

5.1 Introduction

5.1.1 Allergic (extrinsic)

5.1.2 Non-allergic (intrinsic) asthma

6 Global anti-asthma drugs market, by trigger

6.1 Introduction

6.1.1 Child-onset asthma

6.1.2 Adult-onset asthma

6.1.3 Exercise-induced asthma

6.1.4 Cough-induced asthma

6.1.5 Occupational asthma

6.1.6 Nocturnal asthma

6.1.7 Steroid-resistant asthma

7 Global anti-asthma drugs market, by drug class

7.1 Introduction

7.1.1 Bronchodilators (beta agonists, anti-cholinergics, xanthines)

7.1.2 Leukotriene antagonists

7.1.3 Mast cell stabilizers

7.1.4 Corticosteroids

7.1.5 Monoclonal antibody

7.1.6 Others

8 Global anti-asthma drugs market, by therapy

8.1 Introduction

8.1.1 Preventive

8.1.2 Curative

9 Global anti-asthma drugs market, by route of administration

9.1 Introduction

9.1.1 Oral

9.1.2 Inhaled

9.1.3 Intravenous

9.1.4 Subcutaneous

10 Global anti-asthma drugs market, by Regions

10.1 Introduction

10.1.1 Americas

10.1.1.1 North America

10.1.1.2 South America

10.1.2 Europe

10.1.2.1 Germany

10.1.2.2 France

10.1.2.3 UK

10.1.2.4 Italy

10.1.2.5 Spain

10.1.2.6 Rest of Europe

10.1.3 Asia Pacific

10.1.3.1 Japan

10.1.3.2 China

10.1.3.3 India

10.1.3.4 Republic of Korea

10.1.3.5 Rest of Asia Pacific

10.1.4 Middle East & Africa

11 Company Landscape

11.1 Introduction

11.1.1 Mergers Acquisitions

11.1.2 Collaborations

11.1.3 Release/New Product Launch

11.1.4 Other (Expansion, Updates, Partnership)

12 Company Profile

12.1 GlaxoSmithKline plc.

12.1.1 Company Overview

12.1.2 Product/Business Segment Overview

12.1.3 Financials

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Merck & Co., Inc.

12.2.1 Overview

12.2.2 Product/Business Segment Overview

12.2.3 Financials

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 AstraZeneca plc.

12.3.1 Overview

12.3.2 Product/Business Segment Overview

12.3.3 Financials

12.3.4 Key Developments

12.3.5 SWOT Analysis

12.4 F. Hoffmann-La Roche Ltd

12.4.1 Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financials

12.4.4 Key Developments

12.4.5 SWOT Analysis

12.5 Teva Pharmaceutical Industries

12.5.1 Overview

12.5.2 Product/Business Segment Overview

12.5.3 Financials

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Novartis International AG

12.6.1 Overview

12.6.2 Product/Business Segment Overview

12.6.3 Financials

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Boehringer Ingelheim

12.7.1 Overview

12.7.2 Product/Business Segment Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Sunovion Pharmaceuticals Inc.

12.8.1 Overview

12.8.2 Product/Business Segment Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

13 Others

14 Appendix













List of Tables

TABLE 1 GLOBAL ANTI-ASTHMA DRUGS MARKET, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TYPES, 2013-2022 (USD MILLION)

TABLE 3 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TRIGGER, 2013-2022 (USD MILLION)

TABLE 4 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY DRUG CLASS, 2013-2022 (USD MILLION)

TABLE 5 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY THERAPY, 2013-2022 (USD MILLION)

TABLE 6 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2013-2022 (USD MILLION)

TABLE 7 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY REGION, 2013-2022 (USD MILLION)













List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TYPES

FIGURE 4 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TRIGGER

FIGURE 5 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY DRUG CLASS

FIGURE 6 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY THERAPY

FIGURE 7 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 8 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY REGION

FIGURE 9 GLOBAL ANTI-ASTHMA DRUGS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)